Clinical trial
Irinotecan in Treating Children With Refractory Solid Tumors
NCT00004078 · Children's Oncology Group, Other · Completed
Key facts
| NCT number | NCT00004078 |
|---|---|
| Title | Irinotecan in Treating Children With Refractory Solid Tumors |
| Official title | Phase II Trial of Irinotecan in Children With Refractory Solid Tumors |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Previously Treated Childhood Rhabdomyosarcoma and 12 more |
| Intervention type | Drug |
| Interventions | irinotecan hydrochloride |
| Enrollment | 181 |
| Start date | Oct 1, 1999 |
| Primary completion | Oct 1, 2007 |
| First posted | Jan 28, 2003 |
| Last update posted | Jun 14, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: